Thomas Hobby, DO
Internal Medicine · Valdosta, GANPI 1497749733
Payments from drug & device makers
Across 119 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$391
- Novo Nordisk$253
- Pfizer$222
- Johnson & Johnson$195
- Dexcom, Inc.$121
- Merck$120
- plus $581 from 18 others
What the payments were for
- Food & beverage$1,79895%
- Education$855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 20 | $391 |
| Novo Nordisk | 19 | $253 |
| Pfizer | 14 | $222 |
| Johnson & Johnson | 16 | $195 |
| Dexcom, Inc. | 6 | $121 |
| Merck | 8 | $120 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| AstraZeneca | 5 | $69 |
| GSK | 5 | $66 |
| Nestle Healthcare Nutrition Inc. | 2 | $49 |
| Novartis | 1 | $34 |
| AbbVie | 2 | $34 |
| Abbott | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Boston Scientific | 1 | $28 |
| Seqirus USA Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,883 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $159,053 |
| JanuviaSitagliptin Phosphate | 82 | $86,622 |
| OzempicSemaglutide | 33 | $62,228 |
| XareltoRivaroxaban | 64 | $41,007 |
| FarxigaDapagliflozin Propanediol | 33 | $34,328 |
| TrulicityDulaglutide | 31 | $31,449 |
| JardianceEmpagliflozin | 25 | $28,529 |
| MyrbetriqMirabegron | 52 | $24,505 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $17,908 |
| TradjentaLinagliptin | 21 | $17,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,636 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,804 |
| XyostedTestosterone Enanthate | 12 | $7,292 |
| Victoza 2-PakLiraglutide | 11 | $6,732 |
| Potassium Chloride | 372 | $6,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $222 | $159,053158 claims |
| MerckJanuvia, Janumet | $120 | $104,530114 claims |
| Novo NordiskOzempic | $253 | $62,22833 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $45,61846 claims |
| Johnson & JohnsonXarelto | $195 | $41,00764 claims |
| AstraZenecaFarxiga | $69 | $34,32833 claims |
| Lilly USA, LLCTrulicity, Humalog Mix 75-25 | $29 | $33,82742 claims |
| Astellas Pharma US IncMyrbetriq | $391 | $24,50552 claims |
| GSKTrelegy Ellipta | $66 | $14,63613 claims |
| AbbVieSynthroid | $34 | $3,30953 claims |
| Sanofi-aventis U.S. LLCLantus | $100 | $2,78114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Valdosta
- Anna LedfordValdosta$108K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.